Safety study of a new blood clotting medicine in healthy adults
This is an early-stage safety study testing a new experimental medicine that affects blood clotting in people with no serious health conditions. Researchers want to make sure the medicine is safe and well-tolerated before testing it in patients who need it.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18–65 years old and in generally good health with no chronic medical conditions
- Your body mass index (BMI) must be between 18.0 and 32.0, and you must weigh at least 50 kg (110 lbs)
- Your blood clotting tests (APTT, PT, INR, and Factor XI activity) must be normal
- You cannot have hepatitis B or C, cancer, or a history of alcohol or drug abuse
- You agree to avoid activities that could cause serious bleeding and use contraception if applicable for 360 days after the study drug
- You cannot have used prescription medications, investigational drugs, or donated blood within the required timeframes
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This is an early-stage (Phase 1) safety test of a new investigational drug called BW-20805-2-1001 in people without serious health conditions. Researchers want to understand how the drug is tolerated and processed by the body when given as an injection.
This trial tests a new medicine, BW-50218, in healthy volunteers to see how safe it is and how the body processes it. If you are generally healthy and meet the specific requirements below, you may be able to help with early research on this potential treatment.
This trial tests a new medicine called MT1011 given as an injection. Researchers want to see how safe it is and how the body handles it. Healthy people can join to help find the right dose for future studies.
This trial tests the safety of a new drug called HW241045 in healthy volunteers. It helps doctors understand how the drug affects the body and if it causes any side effects.
This trial tests a new drug (VB19055) in healthy volunteers to see how safe it is and how the body processes it. Participants will be watched closely and may help find the right dose for future studies.
This study tests whether KN057, a new preventive medicine, is safe for males with hemophilia A or B. It aims to help prevent bleeding episodes without causing unwanted blood clots.
Hear when a new HV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.